Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies
<jats:p>Effective antitumor immunity in mice requires activation of the type I interferon (IFN) response pathway. IFNα and IFNβ therapies have proven promising in humans, but suffer from limited efficacy and high toxicity. Intratumoral IFN retention ameliorates systemic toxicity, but given the...
Main Authors: | Lutz, Emi A, Agarwal, Yash, Momin, Noor, Cowles, Sarah C, Palmeri, Joseph R, Duong, Ellen, Hornet, Vladlena, Sheen, Allison, Lax, Brianna M, Rothschilds, Adrienne M, Irvine, Darrell J, Spranger, Stefani, Wittrup, K Dane |
---|---|
Other Authors: | Koch Institute for Integrative Cancer Research at MIT |
Format: | Article |
Language: | English |
Published: |
Proceedings of the National Academy of Sciences
2023
|
Online Access: | https://hdl.handle.net/1721.1/146987 |
Similar Items
-
CD8+ T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs
by: Joseph R. Palmeri, et al.
Published: (2024-03-01) -
1224 Tregs constrain CD8 + T cell priming required for curative intratumorally anchored anti-4–1BB immunotherapy
by: Emi A Lutz, et al.
Published: (2023-11-01) -
Co‐Anchoring of Engineered Immunogen and Immunostimulatory Cytokines to Alum Promotes Enhanced‐Humoral Immunity
by: Chang, Jason YH, et al.
Published: (2022) -
An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
by: Cowles, Sarah C., et al.
Published: (2022) -
An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
by: Sarah C. Cowles, et al.
Published: (2022-12-01)